Global bond yields and rate expectations in developed markets now swing with every move in energy prices. This keeps attention on growth companies that can lift earnings even when borrowing costs feel unpredictable. That is where the Healthy high growth potential screener comes in. It filters for stocks that analysts expect to grow earnings and that sit on solid financial foundations. This article highlights three standouts from that list.

The stocks in the article below are just a starting sample, and the full screen surfaced 273 more companies with equally compelling narratives that are not covered here. To identify and analyze those additional candidates with strong earnings growth expectations and solid balance sheets, head straight into the Healthy high growth potential screener.

Ardelyx (ARDX)

Ardelyx focuses on medicines for chronic kidney disease and gastrointestinal disorders, with commercial products IBSRELA for irritable bowel syndrome with constipation and XPHOZAH for phosphate control in adults on dialysis. The company is valued at about US$997 million, which places it at the smaller end of the listed biotech sector.

Ardelyx sits at the crossroads of two large disease areas with IBSRELA and XPHOZAH already generating meaningful product revenue, yet the company still reports losses as it invests in access, sales and its pipeline. Recent guidance cuts around IBSRELA and the loss of Medicare coverage for XPHOZAH underline reimbursement and concentration risks, as does reliance on a narrow product set and higher cost debt. At the same time, analyst forecasts point to faster revenue and earnings growth than the wider US market and a potential move into sustained profitability. For investors who can handle biotech risk, the mix of emerging cash flows, international partnerships and current valuation level presents Ardelyx as an opportunity some may wish to research further.

Ardelyx sits at an awkward crossroads of fast projected growth and real reimbursement risk, and many investors may be missing how those forces could interact. Get the full story in the 4 key rewards and 1 important warning sign

Build your own high growth healthcare shortlist

Ardelyx and the two other stocks in this article all came from a single screen, but the real opportunity is tailoring filters to what matters most to you. Use our flexible Screener to mix growth, valuation and balance sheet strength, or start with any of our curated Investing Ideas for ready made ideas.

York Space Systems (YSS)

York Space Systems builds and operates satellites and provides mission services for U.S. government, national security and commercial customers, using its standardized S CLASS, LX CLASS and M CLASS spacecraft platforms. The company currently generates all of its roughly US$396 million in revenue from Aerospace & Defense activities, and it is valued at about US$1.5b.

York Space Systems sits at the heart of the shift to large satellite constellations for defense and communications, with contracts like the Space Development Agency’s Transport Layer highlighting its ability to produce satellites at scale. Some analysts describe potential for revenue and earnings growth if high volume manufacturing, vertical integration and software driven services succeed in turning current losses into profitability, while recent index inclusion has increased the stock’s visibility with institutional investors. On the other hand, the company is heavily dependent on U.S. defense budgets, firm fixed price contracts and external funding, which can create risks if programs are delayed or costs rise. For investors seeking exposure to the build out of proliferated low earth orbit infrastructure, York is a company that may warrant closer research.

York Space Systems sits between accelerating satellite demand and real contract risk, yet many investors may only see the headline wins. Get the fuller picture in the 4 key rewards and 1 important major warning sign

Chime Financial (CHYM)

Chime Financial is a San Francisco based fintech that offers app based checking, debit, savings, credit builder tools and employee banking benefits to consumers in the US and abroad. The company runs a fee free mobile banking model with products such as SpotMe overdraft support, MyPay earned wage access and Chime Card for building credit. It is valued at about US$11.0b.

Chime Financial sits at the center of app based banking, with 9.1 million active members, rising premium products such as Chime Card and MyPay, and a proprietary ChimeCore platform that management expects to push gross margin close to 90%. Analysts see revenue and earnings growing faster than the wider US market and recent quarters have shown improving revenue, expanding adjusted EBITDA and two consecutive GAAP profitable quarters. However, the stock still prices in a rich P/S multiple and depends entirely on external funding rather than customer deposits. For growth focused investors comfortable with fintech risk, the combination of strong member momentum, new products like Chime Invest and Enterprise, and the potential for higher long term margins may warrant a closer look at what could happen if expectations are met or missed.

Chime Financial’s member growth, premium products and near 90% gross margin ambitions point to a story many investors may not have fully pieced together yet. See how that growth thesis stacks up in the analyst forecasts for Chime Financial

Curious About High Conviction Alternatives

Fresh stock ideas do not stay under the radar for long. Spot potential breakouts while momentum is still building and sentiment has not fully caught up. Get in early.

• Scan for cash rich companies that many investors overlook by running the curated list of solid balance sheet and fundamentals (48 results) before the next wave of interest starts to catch up.
• Explore potential exposure to critical materials by checking the focused 28 best rare earth metal stocks while these producers remain under wider market radar for now.
• Target possible income opportunities while yields are still holding up by reviewing the curated 8 dividend fortresses before prices move and headline yields start dropping.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.